In 2020, Personalized Stem Cells developed and secured FDA approval for a COVID-19 stem cell clinical trial. In October of last year, we announced that we out-licensed our allogeneic stem cell program, including the COVID-19 therapy, to Sorrento Therapeutics....
Mike Dale is President and Chief Operating Officer of Personalized Stem Cells, Inc. (PSC), and co-founder of our parent company, VetStem Biopharma. Mike’s journey is not the typical biotech career path. In the 1970’s Mike had no scientific or biotech aspirations or...
2020 was a whirlwind of a year for most of us. Individuals, families, and businesses all over the world were affected by the global pandemic. Nobody expected the year’s crazy turn of events, and most of us found ourselves in uncharted territory when it came to...
Stem cell therapy may be an effective treatment option for traumatic brain injury.
Our parent company, VetStem Biopharma, recently reached their 15 year anniversary as a member of Biocom, a life science association.
Co-Founder and CEO of Personalized Stem Cells Inc., Dr. Robert Harman, has dedicated the majority of his career to developing stem cell therapy for humans and animals.
Recent literature supports the notion that stem cells have the ability to directly modulate pain.
Nearly two decades’ worth of experience in the veterinary field led to the formation of Personalized Stem Cells, a human adipose-derived stem cell company.
Personalized Stem Cells announces licensing agreement for its allogeneic stem cell program including COVID-19 therapy.
Personalized Stem Cells secured $2.5 million during a Series A round of financing in spite of the current economic crisis.